TNKASE Drug Profile

Summary for Tradename: TNKASE

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TNKASE

Recent Clinical Trials for TNKASE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The First Affiliated Hospital of University of Science and Technology of China	Phase 3
Xinqiao Hospital of Chongqing	Phase 2/Phase 3
The 904th Hospital of PLA (Zhonghua Shi)	Phase 2/Phase 3

See all TNKASE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TNKASE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TNKASE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TNKASE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	10,111,968	2036-08-10	Patent claims search
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	10,112,981	2036-11-15	Patent claims search
Genentech, Inc.	TNKASE	tenecteplase	For Injection	103909	10,130,645	2037-06-20	Patent claims search

TNKASE: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current market position of TNKASE?

TNKASE (tenecteplase), a thrombolytic agent, is approved primarily for acute myocardial infarction (AMI). Manufactured by Genentech/Roche, it entered the market following FDA approval in 2000. As of 2023, TNKASE maintains a moderate share in the thrombolytic space, which is increasingly challenged by alternative therapies.

Market share analysis reveals TNKASE’s reduced dominance due to the rise of percutaneous coronary interventions (PCI) and newer thrombolytics. Despite its established presence, TNKASE faces stiff competition from alteplase (Activase) and regional biosimilars.

How do market dynamics influence TNKASE's position?

Key factors affecting TNKASE:

• Evolving treatment guidelines: American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines favor PCI as first-line therapy for ST-elevation myocardial infarction (STEMI). Thrombolytics, including TNKASE, are now secondary options.
• Technological innovations: Advancements in catheter-based interventions diminish reliance on thrombolytics, reducing TNKASE’s overall market penetration.
• Emerging biosimilars: The entry of biosimilar tenecteplase formulations, especially outside the U.S., increases competition and pressures pricing.
• Regulatory landscape: New approvals for alternative agents or indications, such as deep vein thrombosis (DVT), impact TNKASE’s geographic and therapeutic growth opportunity.
• Reimbursement policies: Payers prioritize cost-effective interventions, favoring PCI over thrombolytic therapy where feasible, influencing TNKASE demand.

Geographic considerations:

• U.S. market: Limited growth prospects, with decline in STEMI thrombolytic use.
• Emerging markets: Higher adoption due to limited access to PCI-capable centers. Countries like India and China show consistent demand growth.
• Europe: Moderate use, constrained by national treatment guidelines and reimbursement policies.

What are the financial projections for TNKASE?

Revenue estimates:

• Historical revenue: Roche reported peak sales of approximately $250 million USD around 2010.
• Recent trends: Revenue declined to roughly $100 million USD in 2022, with ongoing downward pressure.

Market projection:

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2022	100	-	Decline driven by reduced thrombolytic use
2023	85	-15%	Continued market shrinkage
2024	70	-18%	Potential stabilization in emerging markets
2025	60	-14%	Residual demand persists in select regions
2026	50	-16%	Further decline expected

Cost factors:

• Manufacturing: Biosimilar competition may decrease costs for competitors, but Roche's own margins face pressure.
• Pricing: Pricing has declined in tandem with market share, especially outside the U.S.
• Development costs: Limited R&D investment post-2015 for TNKASE reduces financial input; focus shifts to pipeline expansion.

Investment outlook:

With declining sales, Roche is unlikely to invest significantly in TNKASE enhancements. Focus shifts towards novel thrombolytics or alternative indications. Financially, TNKASE remains a cash-generating product mainly from residual markets, rather than growth.

How do competitors and pipeline developments affect TNKASE?

• New thrombolytics: Alternative agents with improved safety profiles are advancing, including microplasmin-based therapies and other bioengineered plasminogen activators.
• Non-thrombolytic therapies: Mechanical reperfusion and dual antiplatelet regimens reduce dependence on thrombolytics, shrinking TNKASE’s market.
• Pipeline advancements: Several late-stage compounds aim to replace or supplement existing thrombolytics, challenging TNKASE's continued relevance.

Summary of key market factors:

• Market share expected to decline by approximately 15-20% annually over the next three years.
• Regions: Stronger demand in emerging markets, stagnation in North America and Europe.
• Revenue: Projected to fall from $85 million in 2023 to roughly $50 million by 2026.
• Competitive landscape: Biosimilar and novel agents exert downward pricing and volume pressure.

Key Takeaways

• TNKASE’s market presence is shrinking due to shifting cardiology treatment strategies favoring PCI.
• Revenue decline is driven by reduced usage, biosimilar competition, and regional treatment guideline shifts.
• Prospects for growth are limited; residual sales mainly in emerging markets.
• Roche's strategic focus appears to be on pipeline diversification beyond TNKASE.

FAQs

1. Will TNKASE regain market share in the future?
No, market trends favor PCI over thrombolytics, and biosimilars further limit TNKASE's growth potential.

2. Which regions offer the most potential for TNKASE sales?
Emerging markets with limited access to PCI, like India and parts of Southeast Asia.

3. Are there new indications for TNKASE beyond myocardial infarction?
Limited exploration exists; most research emphasizes its primary use in AMI.

4. How does biosimilar competition impact TNKASE’s profitability?
It exerts downward pressure on prices and margins, decreasing revenue.

5. What should investors monitor regarding thrombolytic agents?
Pipeline developments, regulatory approvals of competitors, and regional reimbursement policies.

---

References

1. Food and Drug Administration. (2000). TNKASE approval letter. https://www.fda.gov

2. Genentech/Roche. (2022). Annual Report. https://www.roche.com

3. American Heart Association. (2021). Guidelines for the management of acute myocardial infarction. Circulation, 144(4), e92-e210.

4. European Society of Cardiology. (2022). Guideline on the management of myocardial infarction. European Heart Journal, 43, 399-413.

5. IQVIA. (2023). Global thrombolytics market report. https://www.iqvia.com